Indomethacin with or without prophylactic pancreatic stent placement to prevent pancreatitis after ERCP: a randomised non-inferiority trial

医学 胰腺炎 随机对照试验 支架 胆道支架 外科
作者
B. Joseph Elmunzer,Lydia D. Foster,José Serrano,Gregory A. Coté,Steven A. Edmundowicz,Sachin Wani,Raj J. Shah,Ji Young Bang,Shyam Varadarajulu,Vikesh K. Singh,Mouen A. Khashab,Richard S. Kwon,James M. Scheiman,Field F. Willingham,Steven Keilin,Georgios I. Papachristou,Amitabh Chak,Adam Slivka,Daniel Mullady,Vladimir Kushnir
出处
期刊:The Lancet [Elsevier BV]
卷期号:403 (10425): 450-458 被引量:71
标识
DOI:10.1016/s0140-6736(23)02356-5
摘要

Summary

Background

The combination of rectally administered indomethacin and placement of a prophylactic pancreatic stent is recommended to prevent pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP) in high-risk patients. Preliminary evidence suggests that the use of indomethacin might eliminate or substantially reduce the need for stent placement, a technically complex, costly, and potentially harmful intervention.

Methods

In this randomised, non-inferiority trial conducted at 20 referral centres in the USA and Canada, patients (aged ≥18 years) at high risk for post-ERCP pancreatitis were randomly assigned (1:1) to receive rectal indomethacin alone or the combination of indomethacin plus a prophylactic pancreatic stent. Patients, treating clinicians, and outcomes assessors were masked to study group assignment. The primary outcome was post-ERCP pancreatitis. To declare non-inferiority, the upper bound of the two-sided 95% CI for the difference in post-ERCP pancreatitis (indomethacin alone minus indomethacin plus stent) would have to be less than 5% (non-inferiority margin) in both the intention-to-treat and per-protocol populations. This trial is registered with ClinicalTrials.gov (NCT02476279), and is complete.

Findings

Between Sept 17, 2015, and Jan 25, 2023, a total of 1950 patients were randomly assigned. Post-ERCP pancreatitis occurred in 145 (14·9%) of 975 patients in the indomethacin alone group and in 110 (11·3%) of 975 in the indomethacin plus stent group (risk difference 3·6%; 95% CI 0·6–6·6; p=0·18 for non-inferiority). A post-hoc intention-to-treat analysis of the risk difference between groups showed that indomethacin alone was inferior to the combination of indomethacin plus prophylactic stent (p=0·011). The relative benefit of stent placement was generally consistent across study subgroups but appeared more prominent among patients at highest risk for pancreatitis. Safety outcomes (serious adverse events, intensive care unit admission, and hospital length of stay) did not differ between groups.

Interpretation

For preventing post-ERCP pancreatitis in high-risk patients, a strategy of indomethacin alone was not as effective as a strategy of indomethacin plus prophylactic pancreatic stent placement. These results support prophylactic pancreatic stent placement in addition to rectal indomethacin administration in high-risk patients, in accordance with clinical practice guidelines.

Funding

US National Institutes of Health.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
1秒前
2秒前
轻松翰发布了新的文献求助10
2秒前
daomaihu发布了新的文献求助100
3秒前
光亮的新儿完成签到,获得积分10
3秒前
Maestro_S的应助被hzr采纳,获得10
3秒前
3秒前
肖恩完成签到,获得积分10
4秒前
4秒前
入司的应助被白若宇采纳,获得10
4秒前
Maestro_S的应助被白若宇采纳,获得10
4秒前
呼呼呼完成签到,获得积分10
5秒前
怡然破茧完成签到,获得积分10
6秒前
guaiyu完成签到,获得积分10
7秒前
7秒前
7秒前
黄小皮发布了新的文献求助20
7秒前
7秒前
在水一方的应助被周周采纳,获得10
7秒前
8秒前
ChangyuHu发布了新的文献求助10
8秒前
han完成签到,获得积分20
8秒前
8秒前
Hello的应助被高高的凌萱采纳,获得10
9秒前
令狐惜海的应助被日月随安采纳,获得10
9秒前
9秒前
Jasper的应助被活力叫兽采纳,获得10
9秒前
10秒前
10秒前
天天快乐的应助被踏实的酸奶采纳,获得10
10秒前
斯文败类的应助被内向的白竹采纳,获得10
10秒前
10秒前
旅行者8号完成签到 ,获得积分10
10秒前
黄小皮完成签到,获得积分20
10秒前
11秒前
drizzle发布了新的文献求助10
11秒前
cdercder的应助被雪渐霏采纳,获得10
11秒前
独特的海云完成签到 ,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182602
求助须知:如何正确求助?哪些是违规求助? 9572033
关于积分的说明 21821767
捐赠科研通 7779061
什么是DOI,文献DOI怎么找? 3433684
关于科研通互助平台的介绍 2557863
邀请新用户注册赠送积分活动 2479732